Evidence map›Paper›PMID 25748426›Full record

Trial reportPloS one2015

Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan.

Masato Ogishi, Hiroshi Yotsuyanagi, Takeya Tsutsumi, Hiroyuki Gatanaga, Hirotaka Ode, Wataru Sugiura, Kyoji Moriya, Shinichi Oka, Satoshi Kimura, Kazuhiko Koike

Open access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Masato OgishiDepartment of Internal Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan.
Hiroshi YotsuyanagiDepartment of Internal Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan.
Takeya TsutsumiDepartment of Internal Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan.
Hiroyuki GatanagaAIDS Clinical Center, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
Hirotaka OdeDepartment of Infectious Diseases and Immunology, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan.
Wataru SugiuraDepartment of Infectious Diseases and Immunology, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan.
Kyoji MoriyaDepartment of Internal Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan.
Shinichi OkaAIDS Clinical Center, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
Satoshi KimuraDirector, Tokyo Teishin Hospital, Tokyo, Japan; President, Tokyo Health Care University, Tokyo, Japan.
Kazuhiko KoikeDepartment of Internal Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan.
The University of Tokyo · JPNagoya Medical Center · JPNational Center for Global Health and Medicine · JPTokyo Health Care University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pre-existing low-frequency resistance-associated variants (RAVs) may jeopardize successful sustained virological responses (SVR) to HCV treatment with direct-acting antivirals (DAAs). However, the potential impact of low-frequency (∼0.1%) mutations, concatenated mutations (haplotypes), and their association with genotypes (Gts) on the treatment outcome has not yet been elucidated, most probably owing to the difficulty in detecting pre-existing minor haplotypes with sufficient length and accuracy. Herein, we characterize a methodological framework based on Illumina MiSeq next-generation sequencing (NGS) coupled with bioinformatics of quasispecies reconstruction (QSR) to realize highly accurate variant calling and genotype-haplotype detection. The core-to-NS3 protease coding sequences in 10 HCV monoinfected patients, 5 of whom had a history of blood transfusion, and 11 HCV/HIV coinfected patients with hemophilia, were studied. Simulation experiments showed that, for minor variants constituting more than 1%, our framework achieved a positive predictive value (PPV) of 100% and sensitivities of 91.7-100% for genotyping and 80.6% for RAV screening. Genotyping analysis indicated the prevalence of dominant Gt1a infection in coinfected patients (6/11 vs 0/10, p = 0.01). For clinical samples, minor genotype overlapping infection was prevalent in HCV/HIV coinfected hemophiliacs (10/11) and patients who experienced whole-blood transfusion (4/5) but none in patients without exposure to blood (0/5). As for RAV screening, the Q80K/R and S122K/R variants were particularly prevalent among minor RAVs observed, detected in 12/21 and 6/21 cases, respectively. Q80K was detected only in coinfected patients, whereas Q80R was predominantly detected in monoinfected patients (1/11 vs 7/10, p < 0.01). Multivariate interdependence analysis revealed the previously unrecognized prevalence of Gt1b-Q80K, in HCV/HIV coinfected hemophiliacs [Odds ratio = 13.4 (3.48-51.9), p < 0.01]. Our study revealed the distinct characteristics of viral quasispecies between the subgroups specified above and the feasibility of NGS and QSR-based genetic deconvolution of pre-existing minor Gts, RAVs, and their interrelationships.

Indexed as

Genetic VariationHaplotypesDEAD-box RNA HelicasesFemaleHemophilia AHepacivirusHepatitis CHIV InfectionsHumansJapanMaleNucleoside-TriphosphatasePrevalenceSerine EndopeptidasesViral Nonstructural ProteinsViral ProteasesDEAD-box RNA HelicasesNS3 protein, hepatitis C virusNucleoside-TriphosphataseSerine EndopeptidasesViral Nonstructural ProteinsViral Proteases

Identifiers

PMID25748426
PMCPMC4351984
OpenAlexW2002137117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.